Brind.
  1. Johnson & Johnson sought FDA approval for TREMFYA via sBLA, involving Dr. Philip J. Mease and the University of Washington School of Medicine in Seattle.

Tremfya is gaining traction among US gastroenterologists due to its strong efficacy and safety profile, leading to increased market share against older TNF inhibitors.

1 report, 1 independent Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Tremfya is gaining traction among US gastroenterologists due to its strong efficacy and safety profile, leading to increased market share against older TNF inhibitors.

Keep exploring

Part of

Johnson & Johnson sought FDA approval for TREMFYA via sBLA, involving Dr. Philip J. Mease and the University of Washington School of Medicine in Seattle. All 1 developments

Coverage

Newest first; wire copies grouped
  • GlobeNewswireJohnson & Johnson Innovative Medicine’s Tremfya Gains Momentum in Crohn’s Disease, Outpacing Eli Lilly’s Omvoh and Challenging AbbVie’s Skyrizi Strong efficacy and safety perceptions, as well as favo